Browse the evidence

Behavioral weight management programs (BWMPs) involving diet and/or exercise do not harm mental health despite common weight regain, and may improve specific mental health dimensions (psychological wellbeing, self-esteem, depression, anxiety) at and after program end.

If you are doing a weight loss program, don't worry if you regain some weight; it doesn't mean your mental health will suffer. In fact, these programs often improve your self-esteem, anxiety, and overall wellbeing, even after the program ends. Focus on the behavioral changes and mental health benefits, not just the scale.

Obesity is a chronic disease of dysregulated energy balance involving neuroendocrine factors, requiring lifelong, multimodal management (lifestyle, pharmacotherapy, surgery) tailored to individual patient characteristics and evolving goals.

Treat obesity as a chronic disease requiring long-term management. Work with your healthcare provider to create a personalized plan involving lifestyle changes, medications, or surgery based on your specific health needs and goals. Regular follow-up is essential to adjust treatment as your needs change.

High-intensity interval exercise (HIIE) induces time-dependent transcriptomic changes in skeletal muscle that persist for at least 48 hours, with the magnitude of expression for 60% of genes being influenced by cardiorespiratory fitness.

To maximize molecular adaptations, ensure your exercise intensity is relative to your current fitness level (e.g., using lactate threshold or max work rate) rather than a fixed percentage. Recognize that the body's molecular response to exercise continues for up to 48 hours, with significant changes occurring well after the workout ends. This applies to both men and women when fitness levels are comparable.

High-fat and fasting diets increase lipid oxidation (LIPOX) and lower respiratory quotient (RQ), which is directly associated with increased circulating acylcarnitines and decreased glycerophospholipids, indicating a coordinated metabolic shift toward mitochondrial beta-oxidation.

When you eat a high-fat or fasted state, your body shifts to burning fat for fuel. This shift is measurable through specific blood markers (acylcarnitines) and breathing ratios (RQ). If you want to increase fat oxidation, reducing carbohydrate intake or fasting are effective strategies.

High-carbohydrate overfeeding increases 24-hour energy expenditure (EE) more than high-fat or fasting diets, despite being associated with lower lipid oxidation.

If you are overfeeding, a high-carbohydrate diet may result in higher total energy expenditure than a high-fat diet. This does not mean high-carb is better for weight loss, but it does show that the body burns more total energy when processing high carbs in an overfed state.

Semaglutide significantly improves MASH resolution and reduces liver steatosis and enzymes, but does not significantly improve fibrosis regression, with efficacy increasing at doses ≥2.0 mg/week and durations ≥12 months.

If you have MASH, semaglutide is a strong option to resolve active liver inflammation and reduce liver fat, especially if you can tolerate doses of 2.0 mg/week or higher for at least a year. However, do not expect it to reverse existing liver scarring (fibrosis). The primary benefit is halting active injury and reducing metabolic risk factors like weight and blood sugar, which indirectly protects the liver.

SGLT2 inhibitors reduce cardiovascular death, heart failure hospitalizations, and kidney disease progression in patients with type 2 diabetes, regardless of baseline glycemic control.

If you have Type 2 Diabetes and heart disease, heart failure, or kidney issues, ask your doctor about SGLT2 inhibitors (like Jardiance, Farxiga, or Invokana). These drugs protect your heart and kidneys directly, offering significant benefits even if your blood sugar is already well-controlled. They are now a standard part of care for high-risk patients, regardless of whether they lower blood sugar significantly.

Semaglutide and tirzepatide reduce cardiovascular risk and improve cardiac function through pleiotropic mechanisms including endothelial protection, anti-inflammation, and inhibition of cardiomyocyte apoptosis, independent of glycemic control.

If you have obesity and existing heart disease, semaglutide (2.4 mg weekly) significantly lowers your risk of heart attack, stroke, and cardiovascular death, even if you do not have diabetes. This benefit comes from direct protection of your blood vessels and heart muscle, not just weight loss.

Semaglutide reduces major adverse cardiovascular events (MACE) by 26% in patients with type 2 diabetes at high cardiovascular risk.

If you have type 2 diabetes and are at high risk for heart problems, semaglutide (Ozempic) is not just for weight loss; it has been proven to reduce the risk of heart attack, stroke, and cardiovascular death by 26%. This makes it a critical tool for protecting your heart health alongside managing your blood sugar.

GLP-1/GIP receptor agonists (liraglutide, semaglutide, tirzepatide) produce significant weight loss (8-21%) but discontinuation leads to rapid weight regain (approx. two-thirds) and return of cardiovascular risk factors, necessitating long-term maintenance strategies.

GLP-1 medications are highly effective for weight loss but are not a one-time fix. You must plan for long-term use or a structured maintenance program to prevent weight regain. Discuss with your doctor how to manage side effects (like nausea) through diet and titration, and ensure you have a plan for ongoing care, as stopping the medication often leads to regaining two-thirds of the lost weight.

GLP-1 receptor agonists (GLP1RAs) reduce the risk of total stroke by approximately 16-17% and non-fatal stroke by 15-16% in patients with type 2 diabetes, independent of their effects on weight loss.

If you have type 2 diabetes and are at high risk for heart disease or stroke, ask your doctor about GLP-1 receptor agonists. These medications not only help with blood sugar and weight but have been shown in large studies to significantly lower your risk of having a stroke. This benefit exists even if you don't lose a lot of weight.

GLP-1 receptor agonists (e.g., Semaglutide) are effective for weight loss and metabolic stabilization but cause significant weight regain (rebound) upon discontinuation, necessitating long-term management or transition to surgery.

GLP-1 medications like Semaglutide are powerful tools for weight loss and fixing metabolic issues, but they are not a one-time cure. If you stop taking them, you will likely regain most of the weight. Use them to stabilize your health and weight before considering skin removal surgery, or commit to long-term use if surgery is not an option.

Semaglutide (2.4 mg) reduces the risk of major adverse cardiovascular events (MACE) by 20% in patients with cardiovascular disease and obesity, independent of diabetes status.

If you have heart disease and are overweight, Semaglutide may offer a 20% reduction in your risk of heart attack, stroke, or cardiovascular death, in addition to helping with weight loss. This benefit exists even if you do not have diabetes.

GLP-1 receptor agonists provide cardiovascular and renal benefits, including reduced risk of major adverse cardiovascular events (MACE) and improved heart failure symptoms, independent of weight loss.

GLP-1 and GIP/GLP-1 agonists offer significant cardiovascular and renal benefits, reducing the risk of heart attacks, strokes, and heart failure hospitalizations. These benefits occur independently of weight loss, suggesting direct protective effects on organs. They are recommended for patients with obesity and cardiovascular disease or heart failure.

Obesity and central adiposity drive insulin resistance and hypertension through the dysregulation of adipokines (elevated TNF-α, IL-6, leptin; reduced adiponectin), which activate inflammatory pathways like NF-κB and RAAS.

Excess body fat, especially around the abdomen, releases inflammatory hormones (adipokines) that block insulin action and raise blood pressure. This biological process, driven by cytokines like TNF-α and IL-6, makes weight loss and blood sugar control harder. Addressing obesity through lifestyle changes or medications that target these pathways can improve insulin sensitivity and reduce cardiovascular risk.

Resmetirom (80-100 mg daily) improves histological MASH resolution and fibrosis in patients with F2-F3 fibrosis without requiring significant weight loss, while also lowering LDL cholesterol.

If you have moderate to advanced liver scarring (F2-F3) from metabolic issues, Resmetirom is a new daily pill option. It works by targeting liver-specific thyroid receptors to reduce inflammation and scarring, and it also lowers bad cholesterol. You do not need to lose a lot of weight for it to work on the liver, though diet and exercise are still recommended.

GLP-1 receptor agonists (GLP-1RA) significantly reduce major adverse cardiovascular events (MACE), all-cause mortality, and heart failure hospitalizations in patients with type 2 diabetes and obesity, with specific benefits observed in heart failure with preserved ejection fraction (HFpEF).

If you have Type 2 Diabetes and Obesity, especially with heart issues, GLP-1 medications like Semaglutide or Liraglutide are highly effective. They not only help with weight loss but significantly reduce the risk of heart attacks, strokes, and heart failure hospitalizations. While injections can cause temporary stomach issues, the long-term protection for your heart is substantial. Discuss these options with your doctor, particularly if you have heart failure with preserved ejection fraction.

Smoking cessation leads to significant weight gain and metabolic deterioration, but the cardiovascular benefits of quitting smoking outweigh these risks.

If you smoke, quit. You will likely gain some weight, but this does not cancel out the massive heart health benefits of quitting. Focus on healthy habits to manage weight, but do not let the fear of weight gain stop you from quitting.

Semaglutide 2.4 mg weekly reduces cardiovascular mortality, myocardial infarction, and stroke in overweight/obese patients without diabetes but with cardiovascular disease.

If you have obesity and existing heart disease, even without diabetes, semaglutide 2.4 mg weekly can significantly reduce your risk of heart attack, stroke, and death. This is a critical benefit beyond weight loss. Discuss this with your doctor to see if you qualify for this treatment.

GLP-1 receptor agonists reduce cardiovascular risk in patients with obesity and established cardiovascular disease, even in the absence of diabetes.

For individuals with obesity and existing heart disease, GLP-1 medications like semaglutide can significantly reduce the risk of major cardiovascular events and promote weight loss, even without diabetes. This makes them a valuable tool for comprehensive heart health management.

Glucagon-like peptide-1 (GLP-1) receptor agonists, specifically tirzepatide, significantly reduce AHI and improve hypoxic burden in patients with moderate-to-severe OSA and obesity, independent of or adjunct to CPAP use.

If you have moderate to severe sleep apnea and obesity, ask your doctor about Tirzepatide. Recent clinical trials show it significantly reduces breathing interruptions during sleep and improves oxygen levels, even for those already using CPAP. It has received FDA approval for this use. Be prepared for mild stomach issues initially, which usually subside.

Macronutrient composition (carbohydrate vs fat vs protein ratios) does not significantly impact weight loss outcomes when total caloric intake is controlled, provided the diet is sustainable.

You do not need to follow a specific 'low-carb' or 'low-fat' diet to lose weight. Studies show that when calories are equal, the source of those calories (carbs vs fat vs protein) matters less for weight loss than the total amount. Focus on finding a dietary pattern you enjoy and can stick with long-term.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce major adverse cardiovascular events (MACE) and all-cause mortality in patients with type 2 diabetes, with specific agents like liraglutide and semaglutide demonstrating superior efficacy.

If you have Type 2 Diabetes and are at risk for heart problems, ask your doctor about GLP-1 medications like semaglutide or liraglutide. These drugs not only help control blood sugar but have been proven to significantly lower your risk of heart attack, stroke, and death. Newer oral versions are available if you dislike injections.

SGLT-2 inhibitors (SGLT-2is) reduce major adverse cardiovascular events and renal outcomes in patients with Type 2 Diabetes, with specific agents like empagliflozin and canagliflozin showing significant benefits.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT-2 inhibitors like empagliflozin or canagliflozin. These pills help your body remove excess sugar through urine, which has been shown to significantly protect your heart and kidneys. They are often used alongside metformin.